-
Mashup Score: 0DOACs Reduce Dementia Risk vs Warfarin in A-Fib - Psychiatry Advisor - 7 month(s) ago
For patients with atrial fibrillation (AF), the use of direct-acting oral anticoagulants (DOACs) significantly reduces dementia risk.
Source: www.psychiatryadvisor.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences - 7 month(s) ago
The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk.
Source: cardiovascularbusiness.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0DOACs Reduce Dementia Risk in Asian AFib Patients Compared to Traditional Blood Thinners - American College of Cardiology - 8 month(s) ago
Contact: Katie Glenn, kglenn@acc.org, The use of direct oral anticoagulants (DOACs) was associated with a reduction in dementia risk compared to traditional blood thinners — like warfarin — in atrial fibrillation patients, particularly in Asian patients. According to a study published today in JACC: Asia, this benefit may reverse with increased age and necessitates further follow-up study. “Asian patients are more likely to be sensitive to vitamin K antagonism, which puts them at high risk for bleeding
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Switching From VKA to NOAC in Frail Patients With AF: Frail-AF Trial - American College of Cardiology - 8 month(s) ago
Geoffrey D. Barnes, MD, MSc, FACC
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
AbstractAims. The impact of adherence to oral anticoagulation has not been reported in terms of absolute risk, which would enhance patients’ understanding and t
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 19
AbstractAims. Data on non-vitamin K antagonist oral anticoagulants (NOACs) use in patients with atrial fibrillation (AF) and frailty are scarce. Therefore, the
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation - 1 year(s) ago
Oral anticoagulation therapy has evolved beyond vitamin K antagonists to include oral direct thrombin inhibitors and factor Xa inhibitors. Collectively known as ‘direct oral anticoagulants’, this class of medications represents the current standard of care for the prevention and treatment of common thrombotic disorders, including atrial fibrillation and venous thromboembolism. Medications that…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0
Researchers sought to compare the safety and efficacy of direct oral anticoagulants with vitamin-K antagonists in patients with thrombotic antiphospholipid syndrome.
Source: Rheumatology AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Researchers sought to compare the safety and efficacy of direct oral anticoagulants with vitamin-K antagonists in patients with thrombotic antiphospholipid syndrome.
Source: The Cardiology AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Edoxaban an ‘Appropriate Alternative’ to Standard-of-Care Anticoagulants for Thromboembolism Prevention in Children: Phase 3 Data - 1 year(s) ago
The direct oral anticoagulant (DOAC) edoxaban is a potential alternative mode of thromboprophylaxis in children with cardiac disease showing low rates of clinically relevant bleeding (CRB) and thrombo
Categories: Cardiology News and Journals, Latest HeadlinesTweet
Compared with warfarin, DOAC use significantly decreased dementia risk among #AFib patients, according to a systematic review & meta-analysis in #JACCAsia. @PsychiatryAdv reports on the findings here: https://t.co/uF5RLEMU0A #NOAC